

# Eleanor Mp Wilson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4720126/publications.pdf>

Version: 2024-02-01

41  
papers

1,215  
citations

567281

15  
h-index

377865

34  
g-index

41  
all docs

41  
docs citations

41  
times ranked

2076  
citing authors

#	ARTICLE	IF	CITATIONS
1	Observed transaminitis with a unique bacteriophage therapy protocol to treat recalcitrant Staphylococcal biofilm infections. <i>Infection</i> , 2022, 50, 281-283.	4.7	10
2	Type I interferons and TGF- $\beta$ 2 cooperate to induce liver fibrosis during HIV-1 infection under antiretroviral therapy. <i>JCI Insight</i> , 2022, 7, .	5.0	6
3	Higher Levels of Fibrosis in a Cohort of Veterans with Chronic Viral Hepatitis are Associated with Extrahepatic Cancers. <i>Journal of Clinical and Experimental Hepatology</i> , 2021, 11, 195-200.	0.9	7
4	Successful Treatment of a Recalcitrant Staphylococcus epidermidis Prosthetic Knee Infection with Intraoperative Bacteriophage Therapy. <i>Pharmaceuticals</i> , 2021, 14, 231.	3.8	28
5	Potential Use of Adjuvant Bacteriophage Therapy With Debridement, Antibiotics, and Implant Retention Surgery to Treat Chronic Prosthetic Joint Infections. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab277.	0.9	16
6	Outcomes in Hepatitis C Positive Liver Transplantation: Timing of Direct-Acting Antiviral Treatment and Impact on Graft Fibrosis. <i>Viruses</i> , 2021, 13, 1831.	3.3	3
7	High prevalence of gastrointestinal manifestations among Cytomegalovirus end-organ disease in the combination antiretroviral era. <i>Journal of Virus Eradication</i> , 2021, 7, 100052.	0.5	2
8	851. Rate of Sexually Transmitted Infections and Engagement in HIV Pre-Exposure Prophylaxis at the Veterans Affairs Maryland Health System. <i>Open Forum Infectious Diseases</i> , 2021, 8, S515-S516.	0.9	0
9	Reconstitution of T follicular helper-humoral immune axis with elimination of hepatitis C virus. <i>Scientific Reports</i> , 2020, 10, 19924.	3.3	4
10	1067. Interferon-free Hepatitis C Treatment Increases Surrogates of Cardiovascular Disease Risk in Black Veterans. <i>Open Forum Infectious Diseases</i> , 2020, 7, S562-S563.	0.9	0
11	1060. Evaluation of ALT at Sustained Virologic Response (SVR) in Patients with Treated Hepatitis C Virus (HCV) Infection. <i>Open Forum Infectious Diseases</i> , 2020, 7, S559-S559.	0.9	0
12	1057. CpG-adjuvanted Hepatitis B vaccination improves seroprotection rates in Veterans with HIV. <i>Open Forum Infectious Diseases</i> , 2020, 7, S558-S558.	0.9	0
13	Sofosbuvir/Velpatasvir/Voxilaprevir: A Highly Effective Option for Retreatment of Hepatitis C in Difficult-to-treat Patients. <i>Antiviral Therapy</i> , 2019, 24, 1-10.	1.0	8
14	Implementation of a unique hepatitis C care continuum model in Rwanda. <i>Journal of Public Health</i> , 2019, 41, e203-e208.	1.8	5
15	A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY). <i>Journal of Hepatology</i> , 2019, 71, 498-504.	3.7	20
16	Can directly acting antiviral regimens against hepatitis C induce host immune responses?. <i>Future Virology</i> , 2018, 13, 147-150.	1.8	0
17	Chronic Hepatitis B Infection. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1802.	7.4	473
18	Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: Highly effective in a predominantly black male patient population. <i>Journal of Viral Hepatitis</i> , 2018, 25, 205-208.	2.0	6

#	ARTICLE	IF	CITATIONS
19	2194. Hepatitis B Care Cascade Within the VA Maryland Healthcare System. <i>Open Forum Infectious Diseases</i> , 2018, 5, S647-S648.	0.9	0
20	Multitarget Direct-Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus. <i>Hepatology Communications</i> , 2018, 2, 1451-1466.	4.3	21
21	Mechanisms of neuropathogenesis in HIV and HCV: similarities, differences, and unknowns. <i>Journal of NeuroVirology</i> , 2018, 24, 670-678.	2.1	7
22	Hepatitis C genotype change after transplantation utilizing hepatitis C positive donor organs. <i>Transplant Infectious Disease</i> , 2018, 20, e12925.	1.7	2
23	Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. <i>Hepatology International</i> , 2018, 12, 214-222.	4.2	20
24	Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-7.	1.4	18
25	Augmentation of hepatitis C virus-specific immunity and sustained virologic response. <i>Journal of Viral Hepatitis</i> , 2017, 24, 742-749.	2.0	25
26	Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy. <i>Hepatology International</i> , 2017, 11, 161-170.	4.2	26
27	Shortening the duration of therapy for chronic hepatitis C infection. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 832-836.	8.1	35
28	Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers. <i>Annals of Internal Medicine</i> , 2017, 167, 311.	3.9	192
29	Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection. <i>Transplantation Direct</i> , 2017, 3, e229.	1.6	4
30	APOBEC3 proteins can copackage and comutate HIV-1 genomes. <i>Nucleic Acids Research</i> , 2016, 44, 7848-7865.	14.5	41
31	Virologic Response following Asunaprevir/Daclatasvir with or without Beclabuvir for Treatment of HCV Genotype 1 in Patients Co-Infected with HIV. <i>Journal of Hepatology</i> , 2016, 64, S760-S761.	3.7	4
32	Hepatitis C genotype 3 disease. <i>Hepatology International</i> , 2016, 10, 861-870.	4.2	26
33	Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 21-36.	3.0	9
34	Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection. <i>Annals of Internal Medicine</i> , 2015, 163, 899-907.	3.9	53
35	Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease. <i>Clinical Infectious Diseases</i> , 2015, 62, civ897.	5.8	31
36	Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort. <i>Aids</i> , 2014, 28, 831-840.	2.2	81

#	ARTICLE	IF	CITATIONS
37	Cytomegalovirus immune reconstitution inflammatory syndrome manifesting as sialadenitis in an HIV-infected patient. <i>Aids</i> , 2013, 27, 1833-1835.	2.2	3
38	HIV diagnosis and testing: what every healthcare professional can do (and why they should). <i>Oral Diseases</i> , 2013, 19, 431-439.	3.0	6
39	Pharmacokinetics of Anidulafungin in Pleural Fluid during the Treatment of a Patient with Candida Emyema. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2478-2480.	3.2	20
40	Sixty-year-old man with slowly expanding nodular plaque on the thigh. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 1083-1087.	1.2	3
41	Case Report and Review of Management of HIV/HCV Coinfection After Treatment Failure. <i>Current Treatment Options in Infectious Diseases</i> , 0, , .	1.9	0